Tissue Regeneration Company CollPlant is Coming to Nasdaq
Already listed on the Tel Aviv Stock Exchange, the Israel-based company is listing on Nasdaq as part of its September investment agreement with Lichtenstein-based Alpha Capital Anstalt
Tissue regeneration company CollPlant Holdings Ltd. will be listing on Nasdaq in the next few days, under the ticker CLGN. On Tuesday, the Israel-based outfit announced Nasdaq has approved its latest registration statement, submitted Monday. The company does not intend to raise funds as part of the listing.
For daily updates, subscribe to our newsletter by clicking here.
Established in 2004, Collplant develops and manufactures collagen-based regenerative medical treatments and bio-ink used in 3D printing of tissues and organs. The company combined human genes and tobacco plant DNA to create plants from which human collagen can be harvested.
CollPlant's bio-ink. Photo: CollPlant Holdings Ltd.
In September 2017 Collplant announced a $5 million private investment agreement with Lichtenstein-based Alpha Capital Anstalt, a hedge fund controlled by Austrian business magnet Martin Schlaff. As part of the agreement, CollPlant has agreed to list on Nasdaq and has submitted several registration statements to the U.S. Securities and Exchange Commission since November.
- Collplant Secures $7.4 million in Private Placement
- Collplant Takes a Step Towards 3D Organ Printing
- Nasdaq to Launch a Program Supporting Israeli Growth Companies
Collplant will remain registered on the Tel Aviv Stock exchange under the ticker CLPT. On Nasdaq, the company will offer American Depositary Shares (ADSs), each representing 50 of the company's ordinary shares.
CollPlant’s listing on Nasdaq will increase the company’s global exposure with the potential of facilitating collaborations and increasing its business operations, CollPlant’s CEO Yehiel Tal said in a statement.